Research from More than Moore's
The Society for Immunotherapy of Cancer (SITC)
The Society for Immunotherapy of Cancer (SITC)
The Society for Immunotherapy of Cancer (SITC)
The Society for Immunotherapy of Cancer (SITC) held its 38th Annual Meeting & Pre-Conference Programs (SITC 2023) from November 1st to 5th, 2023, in the vibrant city of San Diego, CA. MtM's Nicholas Young, PhD authored and presented an abstract at the conference entitled "Novel analysis strategy of T-cell receptor NGS data to develop patient-specific clonotype panels and detect minimal residual disease (MRD) in T-cell acute lymphoblastic leukemia (T-ALL)".
Press Coverage of Our Research
The Society for Immunotherapy of Cancer (SITC)
The Society for Immunotherapy of Cancer (SITC)
Blood Cancers Today provides hematologists and oncologists with news, education, and information relevant to their patients and practices, with insight from experts in the field. On November 6, 2023, Melissa Badamo published an article entitled "Novel Analysis Strategy Detects MRD in T-ALL" describing the SITC abstract that was published and presented by Nicholas Young, PhD.
shaping the future of Precision medicine at MTM
Clinical Implementation of Individualized Treatment Strategies in Precision Oncology
MtM's Nicholas Young, PhD is leading an editorial review team at Frontiers in Immunology and Frontiers in Oncology to publish a multidisciplinary article collection covering research advancements and review articles in precision oncology. Anyone interested in reading more about this topic, submitting work for publication, or seeing the final collection can click this link to the Research Topic through the journal.
Precision oncology can be broadly defined as the use of data from clinically approved testing to inform therapeutic decision making or to stratify patients based on disease profiling. Despite recent advancements, clinical implementation of scientific discoveries from novel, commercially developed laboratory tests has been suboptimal and inefficient in the field. Since FDA approvals of cancer therapeutics will be more commonly tumor-agnostic moving forward, physicians will require a better understanding of commercially available clinical tests to be confident in using the results to guide treatment decisions for their patients. Through the publication of this journal collection, the medical community will have a better understanding of the precision oncology testing landscape and the clinical data indicating efficacy with treatment, which could facilitate more widespread future utilization in conventional clinical care.
Since the results of clinical testing in precision oncology can have diagnostic and therapeutic implications and involve considerations of targeted therapy, immunotherapy, cell-based therapy, or even cytotoxic chemotherapy, the interpretation of data and prioritization of testing modalities can be overwhelming. The goal of this Research Topic is to capture a comprehensive collection of journal articles in the field of precision oncology that will collectively provide high-quality clinical evidence and summarize emerging or commercially available laboratory tests to reference for guiding future clinical utilization. Consequently, publication of this collection of research may contribute to a more efficient translation of scientific discoveries into clinical care and improve patient outcomes by facilitating more effective implementation of precision oncology-based treatment strategies.